Validating a Patient-Reported Outcome Measure to Improve Emergency Department Asthma Care: Protocol for an Observational Study.

Publication date: May 29, 2025

Asthma affects 1 in every 12 persons in the United States, resulting in 1. 9 million emergency department (ED) visits annually. However, the lack of patient-reported outcome measures (PROMs) validated for use in the ED limits the evaluation of interventions to improve ED asthma care. To address this knowledge gap, this study protocol will (1) develop and test the validity and reliability of the Patient Reported Outcomes for Acute Asthma Care and Treatment instrument (PROAACT), (2) test whether receiving more guideline-concordant ED care is associated with improved PROAACT responses, and (3) evaluate the association between PROAACT score and subsequent ED revisits and hospitalizations. This is a prospective cohort study of adult patients visiting the ED for acute asthma exacerbation across 3 EDs at an urban, tertiary care health system. Eligible patients are 18 years or older, have a prior diagnosis of asthma (self-reported or documented in the electronic health record), are English-speaking, and experiencing an ED visit for asthma exacerbation as determined by the treating clinician. Enrolled participants complete an initial PROM survey during their ED visit assessing their symptoms in the preceding 7 days, then complete a follow-up survey 7 days after ED discharge assessing changes in the symptoms in the subsequent 7 days. To test whether guideline-concordant care is associated with improved PROAACT scores, we will conduct a retrospective chart review of medications ordered during the ED visit, and then compare guideline adherence to changes in PROAACT scores. To test whether improved PROAACT scores are associated with fewer return ED visits and hospitalizations, we will extract all-cause ED visits and hospitalizations within 30 days from a regional health information exchange, and then compare usage to changes in PROAACT scores. We will use item response theory to develop scale responses based on summed item responses, which will allow us to test associations with clinical outcomes, including adherence to guideline-recommended care and return ED visits and hospitalizations. Recruitment is ongoing and has experienced numerous challenges related to the COVID-19 pandemic. To date, we have enrolled over 250 participants and have completed over 200 follow-ups. Recruitment is expected to conclude in spring 2025. Our study is intended to validate the use of PROMs during ED visits for acute asthma exacerbation among adult patients. Completion of the proposed aims will result in one of the first PROMs intended for use among adult ED patients and support the feasibility of collecting PROMs in the ED setting. Clinical Trials. gov NCT04349020; https://clinicaltrials. gov/study/NCT04349020. DERR1-10. 2196/67195.

Open Access PDF

Concepts Keywords
Asthma Adult
Hospitalizations Asthma
Proms asthma
emergency care
Emergency Service, Hospital
Female
Hospitalization
Humans
Male
Middle Aged
patient-reported outcomes
Prospective Studies
Reproducibility of Results

Semantics

Type Source Name
disease MESH Emergency
disease MESH Asthma
pathway KEGG Asthma
disease MESH COVID-19 pandemic
drug DRUGBANK Methylphenidate
drug DRUGBANK N-Cyclohexyltaurine
disease MESH low socioeconomic status
disease MESH complications
disease IDO blood
disease MESH Dyspnea
drug DRUGBANK Tropicamide
disease MESH Anxiety
disease IDO history
disease MESH dementia
disease MESH psychosis
disease MESH heart disease
disease MESH gastrointestinal hemorrhage
disease MESH myocardial infarction
disease MESH pulmonary embolism
disease MESH aortic dissection
disease MESH ectopic pregnancy
disease MESH subarachnoid hemorrhage
disease MESH stroke
disease MESH infection
disease MESH chronic obstructive pulmonary disease
disease IDO facility
drug DRUGBANK Etoperidone
disease MESH educational attainment
disease IDO site
drug DRUGBANK Magnesium
disease IDO quality
disease MESH chronic conditions
disease MESH Drug Abuse
disease MESH Allergy
disease IDO process
drug DRUGBANK Coenzyme M
drug DRUGBANK Alpha-1-proteinase inhibitor
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)